<DOC>
	<DOCNO>NCT02642094</DOCNO>
	<brief_summary>To examine whether rapamycin reduce malignant marker aberrant mammary stem/progenitor cell ( MaSCs ) number surgical specimen</brief_summary>
	<brief_title>Aging Mammary Stem Cells Breast Cancer Prevention</brief_title>
	<detailed_description>A non-randomized , open-label , phase II , window opportunity trial carry see 5-7 day rapamycin treatment reduce malignant marker aberrant MaSC number</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Women within 5080 year age Postmenopausal woman define : 1 . Prior bilateral oophorectomy 2 . Age ≥60 3 . Age &lt; 60 amenorrhea 12 month ( absence chemotherapy , tamoxifen , toremifen , ovarian suppression ) FSH estradiol postmenopausal range local laboratory . Women diagnose DCIS ADH lesion detect pathology Women schedule mastectomy lumpectomy DCIS ADH diagnosis Women childbearing potential willing practice 2 form contraception , one must barrier method least 30 day last dose rapamycin . Women childbearing potential must negative serum pregnancy test time enrollment . Patients must able swallow retain oral medication . All patient must give sign , informed consent prior registration study . Patients must normal organ marrow function define : 1 . Leukocytes ≥ 3,000/uL 2 . Absolute neutrophil count ≥ 1,500/uL 3 . Platelets ≥ 100,000/uL 4 . AST ≤ 2.5 X ULN 5 . ALT ≤ 2.5 X ULN 6 . Total bili ≤ 1.5 X ULN Direct bili ≤ 1 X ULN Women old 80 year younger 50 year age . Women pregnant . Women receive concomitant treatment DCIS/ADH Women take rapamycin another diagnosis . Women allergy rapamycin derivative . Active infection require systemic therapy . Patients take pill contain herbal ( alternative ) medicine NOT eligible participation . Patients must medications time registration . Immunocompromised subject , include patient human immunodeficiency virus Women currently take strong CYP3A4 inducer inhibitor . Drugs coadministered rapamycin include limit : Calcium channel blocker : nicardipine , Antifungal agent : clotrimazole , fluconazole , Antibiotics : troleandomycin , Gastrointestinal prokinetic agent : cisapride , metoclopramide , Other drug : bromocriptine , cimetidine , danazol , HIVprotease inhibitor ( e.g. , ritonavir , indinavir ) , Anticonvulsants : carbamazepine , phenobarbital , phenytoin , Antibiotics : rifapentine . Appendix 4 complete list medication . Consent tissue CTRC biorepository ( HSC20070684H ) Patients follow condition complication NOT eligible participation : 1 . GI tract disease result inability take oral medication 2 . Malabsorption syndrome 3 . Require IV alimentation 4 . History prior surgical procedure affect absorption 5 . Uncontrolled inflammatory GI disease ( e.g. , Crohn 's , ulcerative colitis )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>